Product Name:
Akt1-pT308
Product Number:
ab-pk516
Target Full Name: RAC-alpha serine/threonine-protein kinase
Target Alias: Akt; Akt1; Akt1 kinase; C-Akt; Kinase Akt1; PKB; PKB-alpha; PRKBA; V-akt murine thymoma viral oncogene 1; Protein kinase B; RAC; RAC-alpha serine,threonine kinase; RAC-alpha serine/threonine kinase; RAC-PK-alpha; PKBA; hCG_96740; Akt1_NEW; Akt; MGC99656; CCDS9994; B0LPE5; B2RAM5; B3KVH4; B3KXD7; B7Z5R1; Q9BV07; ENSG00000142208
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK515
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T308
Protein UniProt: P31749
Protein SigNET: P31749
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Akt1 (PKBa) sequence peptide Cat. No.: PE-04AIE70
Antibody Immunogen Sequence: TMK(pT)FCG(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues T305 to G311; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues T305 to G311; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 57-62 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: Strong immunoreactivity on protein dot blots with recombinant human Akt2, but not Akt3. Prominent ~78 kDa immunoreactive proteins was evident in HepG2 and MCF7 cells and seastar oocytes. Approximately 130 and 140 kDa cross-reactive proteins were also detected in MCF7 and seastar oocytes.
Related Product 1: Akt1-pT308 blocking peptide
Related Product 2: Akt1-1 pan-specific antibody (Cat. No.: AB-NK129-3)
Related Product 3: Akt1-2 pan-specific antibody (Cat. No.: AB-NK129-4)
Related Product 4: Akt1-3 pan-specific antibody (Cat. No.: AB-NK129-5)
Related Product 5: Akt1-pS473 phosphosite-specific antibody (Cat. No.: AB-PK869)
Related Product 6: Akt1-pS473+pY474 phosphosite-specific antibody (Cat. No.: AB-PK514)
Related Product 7: Akt1-pY315 phosphosite-specific antibody (Cat. No.: AB-PK516)
Related Product 8: Akt1-pY326 phosphosite-specific antibody (Cat. No.: AB-PK517)
Related Product 9: AktSubtide - Akt1 (PKBa) protein kinase substrate peptide
Related Product 10: GSK3b (3-12) KinSub - Glycogen synthase kinase 3-beta (GSK3b) N-terminus (G3-E12, human) peptide; Akt protein kinase substrate peptide
Scientific Background: Akt1 (PKBA) is a protein-serine/threonine kinase of the AGC group and Akt family. It is normally inactive in the cytoplasm. When PI3K is activated by extracellular growth factors, Akt1 is recruited to the cell membrane and phosphorylated by PDK1, mTOR and other protein kinases to become active. This leads to the induction of survival, proliferation, angiogenesis and metabolism pathways. Akt1 is also involved in cell-cycle progression via its inhibitory phosphorylation of cyclin-dependent kinases and activatory phosphorylation of mTOR. This kinase is highly expressed in most tested human tissues. Orthologues of Akt are conserved in a wide range of animals, plants and unicellular eukaryotes. Phosphorylation of T72, S124,S129, S246, T308, Y315,Y326, T450, S473 and Y474 increases Akt1 phosphotransferase activity. TRAF6-induced 'K63'-linked Akt1 ubiquitination is critical for phosphorylation and activation. Phosphorylation of T34 inhibits phosphotransferase activity. Akt1 has been implicated in a wide range of human cancers, including lymphomas, breast, lung, colorectal, pancreatic and prostate cancers.
